Bioxcel therapeutics announces uspto's allowance of patent application for method of treating agitation in alzheimer's disease using oromucosal formulations of dexmedetomidine

Aligns with company's strategic focus on bringing to market bxcl501 for potential acute treatment of agitation for alzheimer's patients

BTAI Ratings Summary

BTAI Quant Ranking